His primary areas of investigation include Immunology, Antigen, Dendritic cell, Immune system and Antigen-presenting cell. Immunology and Interleukin 12 are frequently intertwined in his study. His Antigen research is multidisciplinary, relying on both Monoclonal antibody, Interferon and Antigen presentation.
His work deals with themes such as Interleukin 23, T cell, T helper cell, Immunity and Molecular biology, which intersect with Dendritic cell. His Antigen-presenting cell study combines topics in areas such as Interleukin 21, IL-2 receptor, Immune tolerance and Cell biology. His Multiple myeloma research includes elements of Cancer research and Immunopathology.
His main research concerns Immunology, Multiple myeloma, Internal medicine, Immune system and Cancer research. His study in Antigen, Dendritic cell, Antigen-presenting cell, Natural killer T cell and Immunotherapy is carried out as part of his Immunology studies. CD40 is closely connected to Interleukin 12 in his research, which is encompassed under the umbrella topic of Natural killer T cell.
His biological study spans a wide range of topics, including Monoclonal gammopathy of undetermined significance, Monoclonal and Bone marrow. The various areas that Madhav V. Dhodapkar examines in his Internal medicine study include Gastroenterology, Surgery and Oncology. In his study, CD8 is inextricably linked to T cell, which falls within the broad field of Cancer research.
Madhav V. Dhodapkar spends much of his time researching Multiple myeloma, Internal medicine, Cancer research, Oncology and Lenalidomide. His Multiple myeloma research incorporates elements of Chimeric antigen receptor, Disease, Immune system and Bone marrow. His study in Immune system is interdisciplinary in nature, drawing from both Antigen and Mass cytometry.
Immunology and Pathology are the main topics of his Bone marrow study. Madhav V. Dhodapkar undertakes multidisciplinary studies into Immunology and Childhood leukemia in his work. His Cancer research study combines topics from a wide range of disciplines, such as Cancer, Pomalidomide, T cell, Blockade and Cancer immunotherapy.
Multiple myeloma, Internal medicine, Oncology, Cancer research and Lenalidomide are his primary areas of study. His Multiple myeloma research includes elements of Guideline and Antibody, Monoclonal antibody. His Antibody study deals with the bigger picture of Immunology.
He has included themes like Acquired immune system, T cell, Immune system, Antigen and Chimeric antigen receptor in his Cancer research study. His studies deal with areas such as Cancer cell, Monoclonal gammopathy of undetermined significance, Gammopathy and Bone marrow as well as Acquired immune system. Madhav V. Dhodapkar interconnects Standard of care and Bortezomib in the investigation of issues within Lenalidomide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S;Mehta J;Desikan R;Ayers D.
The New England Journal of Medicine (1999)
Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
Madhav V. Dhodapkar;Ralph M. Steinman;Joseph Krasovsky;Christian Munz.
Journal of Experimental Medicine (2001)
Immune and Clinical Responses in Patients with Metastatic Melanoma to CD34+ Progenitor-derived Dendritic Cell Vaccine
Jacques Banchereau;A. Karolina Palucka;Madhav Dhodapkar;Susan Burkeholder.
Cancer Research (2001)
Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris
Edmund Jd Lee;William L. Trepicchio;Judith L Oestreicher;Debra D Pittman.
Journal of Experimental Medicine (2004)
Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study
Alexander M. Lesokhin;Alexander M. Lesokhin;Stephen M. Ansell;Philippe Armand;Emma C. Scott.
Journal of Clinical Oncology (2016)
Dendritic cell function in vivo during the steady state: a role in peripheral tolerance.
Ralph M. Steinman;Daniel Hawiger;Kang Liu;Laura Bonifaz.
Annals of the New York Academy of Sciences (2003)
A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
Madhav V. Dhodapkar;Madhav V. Dhodapkar;Matthew D. Geller;David H. Chang;Kanako Shimizu.
Journal of Experimental Medicine (2003)
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
David H. Chang;Keren Osman;John Connolly;Anjli Kukreja.
Journal of Experimental Medicine (2005)
Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
Kavita M. Dhodapkar;Joseph Krasovsky;Barbara Williamson;Madhav V. Dhodapkar;Madhav V. Dhodapkar.
Journal of Experimental Medicine (2002)
Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.
Madhav V. Dhodapkar;Ralph M. Steinman.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: